Diacylglycerol Signaling

298 Q.J. Wang
14.6 Concluding Remarks
It has now been well established that the classical and novel PKC isoforms signal
through PKD to regulate a range of fundamental cellular processes. Recent studies
have demonstrated potential roles of the PKC/PKD pathway at all stages of tumor
development. Aberrant PKD expression and activity have been demonstrated and
associated with tumor progression. Thus, the PKC/PKD pathway has emerged as a
novel target for cancer therapy. In the future, more efforts should be devoted to dissect
the specific roles of PKD isoforms at different stages of tumor development, to
advance cellular studies to in vivo animal models of cancer and to exploit the
possibility of targeting the PKC/PKD pathway therapeutically using potent and
selective novel small molecule inhibitors of PKD.
Acknowledgments Work in our laboratory is supported by grants from the National Institutes of
Health.
References
Abbas, A., & Gupta, S. (2008). The role of histone deacetylases in prostate cancer. Epigenetics,
3, 300–309.
Al-Janadi, A., Chandana, S. R., & Conley, B. A. (2008). Histone deacetylation: An attractive
target for cancer therapy? Drugs in R&D, 9, 369–383.
Altschmied, J., & Haendeler, J. (2008). A new kid on the block: PKD1: A promising target for
antiangiogenic therapy? Arteriosclerosis, Thrombosis, and Vascular Biology, 28, 1689–1690.
Auer, A., von Blume, J., Sturany, S., von Wichert, G., Van Lint, J., Vandenheede, J., et al. (2005).
Role of the regulatory domain of protein kinase D2 in phorbol ester binding, catalytic activity,
and nucleocytoplasmic shuttling. Molecular Biology of the Cell, 16, 4375–4385.
Avkiran, M., Rowland, A. J., Cuello, F., & Haworth, R. S. Ullrich (2008). Protein kinase d in the cardiovascular
system: Emerging roles in health and disease. Circulation Research, 102, 157–163.
Bagowski, C. P., Stein-Gerlach, M., Choidas, A., & Ullrich, A. (1999). Cell-type specific phosphorylation
of threonines T654 and T669 by PKD defines the signal capacity of the EGF
receptor. The EMBO Journal, 18, 5567–5576.
Bell, R. M., & Burns, D. J. (1991). Lipid activation of protein kinase C. The Journal of Biological
Chemistry, 266, 4661–4664.
Blumberg, P. M. (1988). Protein kinase C as the receptor for the phorbol ester tumor promoters:
Sixth Rhoads memorial award lecture. Cancer Research, 48, 1–8.
Bollag, W. B., Dodd, M. E., & Shapiro, B. A. (2004). Protein kinase D and keratinocyte proliferation.
Drug News & Perspectives, 17, 117–126.
Bossuyt, J., Helmstadter, K., Wu, X., Clements-Jewery, H., Haworth, R. S., Avkiran, M. et al.
(2008). Ca2+/calmodulin-dependent protein kinase II{delta} and protein kinase D overexpression
reinforce the histone deacetylase 5 redistribution in heart failure. Circulation Research,
102, 695–702.
Bowden, E. T., Barth, M., Thomas, D., Glazer, R. I., & Mueller, S. C. (1999). An invasion-related
complex of cortactin, paxillin and PKCmu associates with invadopodia at sites of extracellular
matrix degradation. Oncogene, 18, 4440–4449.
Brose, N., & Rosenmund, C. (2002). Move over protein kinase C, you’ve got company: Alternative
cellular effectors of diacylglycerol and phorbol esters. Journal of Cell Science, 115,
4399–4411.